Eisai Co. Ltd. v. Hetero Labs Ltd.

Application Number	Patent Number	External Links
-	US6740669	Espacenet Google Patents
-	US7750028	Espacenet Google Patents
-	US8076362	Espacenet Google Patents

COMPLAINT - filed against Hetero Labs Ltd., Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1334542.) - filed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG. (Attachments: # 1 Exhibits A-C, # 2 Civil Cover Sheet)(rwc) (Entered: 07/25/2013)

2013-07-24

1

Download

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 07/25/2013)

2013-07-24

1

View

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/9/13. Date of Expiration of Patent: (See Form).Thirty Month Stay Deadline: 5/14/2016. (rwc) (Entered: 07/25/2013)

2013-07-24

1

View

Disclosure Statement pursuant to Rule 7.1 filed by Eisai Co. Ltd., Eisai Inc. identifying Corporate Parent Eisai Corporation of North America, Corporate Parent Eisai Co. Ltd. for Eisai Inc.. (rwc) (Entered: 07/25/2013)

2013-07-24

1

View

Disclosure Statement pursuant to Rule 7.1 filed by Novartis Pharma AG identifying Corporate Parent Novartis AG for Novartis Pharma AG. (rwc) (Entered: 07/25/2013)

2013-07-24

1

View

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669 B1; 7,750,028 B2; 8,076,362 B2. (rwc) (Entered: 07/25/2013)

2013-07-24

1

View

REQUEST FOR WAIVER of Service sent to Hetero Labs Ltd. on July 29, 2013 by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. Waiver of Service due by 9/30/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

2013-07-30

1

View

WAIVER OF SERVICE returned executed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG: For Hetero Labs Ltd. waiver sent on 7/29/2013, answer due 9/27/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

2013-07-30

1

View

REQUEST FOR WAIVER of Service sent to Hetero USA Inc. on July 29, 2013 by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. Waiver of Service due by 9/30/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

2013-07-30

1

View

WAIVER OF SERVICE returned executed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG: For Hetero USA Inc. waiver sent on 7/29/2013, answer due 9/27/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

2013-07-30

1

View

NOTICE of Appearance by Dominick T. Gattuso on behalf of Hetero Labs Ltd., Hetero USA Inc. (Gattuso, Dominick) (Entered: 08/15/2013)

2013-08-15

1

View

MOTION for Pro Hac Vice Appearance of Attorney Chad A. Landmon, Thomas K. Hedemann and Dan Feng Mei - filed by Hetero Labs Ltd., Hetero USA Inc.. (Gattuso, Dominick) (Entered: 08/15/2013)

2013-08-15

1

View

MOTION for Pro Hac Vice Appearance of Attorney Joseph M. O'Malley, Jr., Bruce M. Wexler, Young J. Park, and Outi Elina Saviharju - filed by Eisai Co. Ltd., Eisai Inc.. (Blumenfeld, Jack) (Entered: 08/26/2013)

2013-08-26

1

View

ANSWER to 1 Complaint, Defenses and, COUNTERCLAIM against Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG by Hetero Labs Ltd., Hetero USA Inc..(Gattuso, Dominick) (Entered: 09/27/2013)

2013-09-27

1

View

Disclosure Statement pursuant to Rule 7.1 filed by Hetero Labs Ltd., Hetero USA Inc. identifying Corporate Parent Hetero Drugs Limited for Hetero Labs Ltd., Hetero USA Inc... (Gattuso, Dominick) (Entered: 10/03/2013)

2013-10-03

1

View

ANSWER to 14 Answer to Complaint, Counterclaim /Answer to Hetero USA Inc.'s and Hetero Labs Ltd.'s Counterclaims by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG.(Noreika, Maryellen) (Entered: 10/18/2013)

2013-10-18

1

View

ORAL ORDER: IT IS HEREBY ORDERED that the parties shall confer regarding proposed dates in the scheduling order and shall submit a proposal to the Court no later than January 6, 2014. The parties are to review the Courts form scheduling order, which is posted at http://www.ded.uscourts.gov (see Chambers, Judge Stark, Forms). ORDERED by Judge Leonard P. Stark on 12/10/13. Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS, 1:13-cv-01281-LPS, 1:13-cv-01282-LPS, 1:13-cv-01284-LPS (ntl) (Entered: 12/10/2013)

2013-12-10

1

View

Amended Disclosure Statement pursuant to Rule 7.1 filed by Hetero Labs Ltd., Hetero USA Inc. identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc... (Gattuso, Dominick) (Entered: 12/13/2013)

2013-12-13

1

View

PROPOSED ORDER [Proposed Scheduling Order] re (15 in 1:13-cv-01284-LPS) Order, by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG, Roxane Laboratories Inc., Hetero Labs Ltd., Hetero USA Inc., Mylan Pharmaceuticals Inc., Glenmark Generics Inc. USA, Glenmark Generics Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Lupin Pharmaceuticals Inc.. (Attachments: # 1 Letter)(Noreika, Maryellen) (Entered: 01/07/2014)

2014-01-07

1

View

SCHEDULING ORDER: Case referred to the Magistrate Judge for the purpose of exploring ADR. Discovery due by 1/23/2015. Status Report due by 10/3/2014. Claim Construction Opening Brief due by 10/10/2014. Claim Construction Answering Brief due by 11/7/2014. A Markman Hearing is set for 12/8/2014 at 09:30 AM in Courtroom 6B. A Pretrial Conference is set for 8/17/2015 at 10:00 AM in Courtroom 6B. Proposed Pretrial Order due by 8/7/2015. A 6-day Bench Trial is set for 9/8/2015 at 09:30 AM in Courtroom 6B. Signed by Judge Leonard P. Stark on 1/21/14. (Attachment: # 1 Form of Pretrial Order)Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS, 1:13-cv-01281-LPS, 1:13-cv-01282-LPS, 1:13-cv-01284-LPS (ntl) (Entered: 01/23/2014)

2014-01-23

1

View

NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG.(Noreika, Maryellen) (Entered: 01/30/2014)

2014-01-30

1

View

MOTION for Pro Hac Vice Appearance of Attorney Edward M. Mathias - filed by Hetero Labs Ltd., Hetero USA Inc.. (Gattuso, Dominick) (Entered: 01/31/2014)

2014-01-31

1

View

STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order to March 3, 2014 - filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 02/24/2014)

2014-02-24

1

View

STIPULATION TO EXTEND TIME to Submit a Proposed Protective Order to March 10, 2014 - filed by Roxane Laboratories Inc., Hetero Labs Ltd., Hetero USA Inc., Mylan Pharmaceuticals Inc., Glenmark Generics Inc. USA, Glenmark Generics Ltd., Glenmark Pharmaceuticals Ltd., Lupin Ltd., Lupin Pharmaceuticals Inc.. (Phillips, John) (Entered: 03/03/2014)

2014-03-03

1

View

ORDER Setting Teleconference: A Telephone Conference is set for 4/14/2014 at 11:15 AM before Judge Christopher J. Burke. Signed by Judge Christopher J. Burke on 3/6/2014. Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS, 1:13-cv-01281-LPS, 1:13-cv-01282-LPS, 1:13-cv-01284-LPS(dlk) (Entered: 03/06/2014)

2014-03-06

1

View

Joint PROPOSED ORDER Protective Order by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 03/10/2014)

2014-03-10

1

View

Joint PROPOSED ORDER Protective Order by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 03/10/2014)

2014-03-10

1

View

NOTICE of Defendants' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery by Hetero Labs Ltd., Hetero USA Inc. (Gattuso, Dominick) (Entered: 03/14/2014)

2014-03-14

1

View

NOTICE OF SERVICE of (1) Plaintiffs' Initial Disclosures Regarding Electronic Systems Information and (2) Plaintiffs' Initial Disclosures Identifying Defendants' Accused Products and Plaintiffs' Asserted Patents filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG.(Noreika, Maryellen) (Entered: 03/14/2014)

2014-03-14

1

View

Joint STIPULATION and Order of Consolidation by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 04/07/2014)

2014-04-07

1

View

ORDER Setting Teleconference: A Telephone Conference is set for 1/26/2015 at 11:00 AM before Judge Christopher J. Burke. Signed by Judge Christopher J. Burke on 4/22/2014. Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS, 1:13-cv-01281-LPS, 1:13-cv-01282-LPS, 1:13-cv-01284-LPS(dlk) (Entered: 04/22/2014)

2014-04-22

1

View

PROPOSED CONSENT JUDGMENT (between Plaintiffs and Hetero Defendants) by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 08/03/2015)

2015-08-03

1

View

CONSENT JUDGMENT re Hetero Labs Ltd. and Hetero USA Inc. Signed by Judge Leonard P. Stark on 8/4/15. Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS (ntl) (Entered: 08/04/2015)

2015-08-04

1

View

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669; 7,750,028; 8,076,362. (ntl) (Entered: 08/04/2015)

2015-08-04

1

View

CASE CLOSED (ntl)

2015-08-04

1

No Actions

Terminate Case - Civil

2015-08-04

1

No Actions

Overview

Parties

Plaintiff

Eisai Co. Ltd. Follow

Represented By

Eisai Inc. Follow

Represented By

Novartis Pharma AG Follow

Represented By

Counter Claimant

Hetero Labs Ltd. Follow

Represented By

Hetero USA Inc. Follow

Represented By

Court & Judges

Patents Involved

Docket Entries

COMPLAINT - filed against Hetero Labs Ltd., Hetero USA Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400.00, receipt number 0311-1334542.) - filed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG. (Attachments: # 1 Exhibits A-C, # 2 Civil Cover Sheet)(rwc) (Entered: 07/25/2013)

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (rwc) (Entered: 07/25/2013)

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 7/9/13. Date of Expiration of Patent: (See Form).Thirty Month Stay Deadline: 5/14/2016. (rwc) (Entered: 07/25/2013)

Disclosure Statement pursuant to Rule 7.1 filed by Eisai Co. Ltd., Eisai Inc. identifying Corporate Parent Eisai Corporation of North America, Corporate Parent Eisai Co. Ltd. for Eisai Inc.. (rwc) (Entered: 07/25/2013)

Disclosure Statement pursuant to Rule 7.1 filed by Novartis Pharma AG identifying Corporate Parent Novartis AG for Novartis Pharma AG. (rwc) (Entered: 07/25/2013)

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669 B1; 7,750,028 B2; 8,076,362 B2. (rwc) (Entered: 07/25/2013)

REQUEST FOR WAIVER of Service sent to Hetero Labs Ltd. on July 29, 2013 by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. Waiver of Service due by 9/30/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

WAIVER OF SERVICE returned executed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG: For Hetero Labs Ltd. waiver sent on 7/29/2013, answer due 9/27/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

REQUEST FOR WAIVER of Service sent to Hetero USA Inc. on July 29, 2013 by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. Waiver of Service due by 9/30/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

WAIVER OF SERVICE returned executed by Eisai Inc., Eisai Co. Ltd., Novartis Pharma AG: For Hetero USA Inc. waiver sent on 7/29/2013, answer due 9/27/2013. (Noreika, Maryellen) (Entered: 07/30/2013)

NOTICE of Appearance by Dominick T. Gattuso on behalf of Hetero Labs Ltd., Hetero USA Inc. (Gattuso, Dominick) (Entered: 08/15/2013)

MOTION for Pro Hac Vice Appearance of Attorney Chad A. Landmon, Thomas K. Hedemann and Dan Feng Mei - filed by Hetero Labs Ltd., Hetero USA Inc.. (Gattuso, Dominick) (Entered: 08/15/2013)

MOTION for Pro Hac Vice Appearance of Attorney Joseph M. O'Malley, Jr., Bruce M. Wexler, Young J. Park, and Outi Elina Saviharju - filed by Eisai Co. Ltd., Eisai Inc.. (Blumenfeld, Jack) (Entered: 08/26/2013)

ANSWER to 1 Complaint, Defenses and, COUNTERCLAIM against Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG by Hetero Labs Ltd., Hetero USA Inc..(Gattuso, Dominick) (Entered: 09/27/2013)

Disclosure Statement pursuant to Rule 7.1 filed by Hetero Labs Ltd., Hetero USA Inc. identifying Corporate Parent Hetero Drugs Limited for Hetero Labs Ltd., Hetero USA Inc... (Gattuso, Dominick) (Entered: 10/03/2013)

ANSWER to 14 Answer to Complaint, Counterclaim /Answer to Hetero USA Inc.'s and Hetero Labs Ltd.'s Counterclaims by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG.(Noreika, Maryellen) (Entered: 10/18/2013)

Amended Disclosure Statement pursuant to Rule 7.1 filed by Hetero Labs Ltd., Hetero USA Inc. identifying Corporate Parent Hetero Drugs Limited, Corporate Parent Hetero Labs Limited for Hetero USA Inc... (Gattuso, Dominick) (Entered: 12/13/2013)

NOTICE OF SERVICE of Plaintiffs' Rule 26(a)(1) Initial Disclosures filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG.(Noreika, Maryellen) (Entered: 01/30/2014)

MOTION for Pro Hac Vice Appearance of Attorney Edward M. Mathias - filed by Hetero Labs Ltd., Hetero USA Inc.. (Gattuso, Dominick) (Entered: 01/31/2014)

STIPULATION TO EXTEND TIME for the parties to submit a proposed protective order to March 3, 2014 - filed by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 02/24/2014)

Joint PROPOSED ORDER Protective Order by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 03/10/2014)

Joint PROPOSED ORDER Protective Order by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 03/10/2014)

NOTICE of Defendants' Initial Disclosures Pursuant to Paragraph 3 of the Default Standard for Discovery by Hetero Labs Ltd., Hetero USA Inc. (Gattuso, Dominick) (Entered: 03/14/2014)

Joint STIPULATION and Order of Consolidation by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 04/07/2014)

PROPOSED CONSENT JUDGMENT (between Plaintiffs and Hetero Defendants) by Eisai Co. Ltd., Eisai Inc., Novartis Pharma AG. (Noreika, Maryellen) (Entered: 08/03/2015)

CONSENT JUDGMENT re Hetero Labs Ltd. and Hetero USA Inc. Signed by Judge Leonard P. Stark on 8/4/15. Associated Cases: 1:13-cv-01279-LPS, 1:13-cv-01280-LPS (ntl) (Entered: 08/04/2015)

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,740,669; 7,750,028; 8,076,362. (ntl) (Entered: 08/04/2015)

CASE CLOSED (ntl)

Terminate Case - Civil

Track Case Updates

Eisai Co. Ltd.

Eisai Inc.

Novartis Pharma AG

Hetero Labs Ltd.

Hetero USA Inc.